FI942728A0 - Lääkeainekoostuksia parenteraaliseen käyttöön - Google Patents

Lääkeainekoostuksia parenteraaliseen käyttöön

Info

Publication number
FI942728A0
FI942728A0 FI942728A FI942728A FI942728A0 FI 942728 A0 FI942728 A0 FI 942728A0 FI 942728 A FI942728 A FI 942728A FI 942728 A FI942728 A FI 942728A FI 942728 A0 FI942728 A0 FI 942728A0
Authority
FI
Finland
Prior art keywords
pharmaceutical compositions
parenteral administration
parenteral
administration
pharmaceutical
Prior art date
Application number
FI942728A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942728A7 (fi
FI942728L (fi
Inventor
Harry Goesta Jalonen
Terttu Marita Heikkilae
Hannu Uolevi Jalonen
Lauri Veikko Matti Kangas
Risto Arvo Sakari Lammintausta
Kauko Oiva Antero Kurkela
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of FI942728A7 publication Critical patent/FI942728A7/fi
Publication of FI942728L publication Critical patent/FI942728L/fi
Publication of FI942728A0 publication Critical patent/FI942728A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI942728A 1991-12-10 1992-12-10 Lääkeainekoostuksia parenteraaliseen käyttöön FI942728A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919126209A GB9126209D0 (en) 1991-12-10 1991-12-10 Drug formulations for parenteral use
PCT/FI1992/000339 WO1993011757A1 (en) 1991-12-10 1992-12-10 Drug formulations for parenteral use

Publications (3)

Publication Number Publication Date
FI942728A7 FI942728A7 (fi) 1994-06-10
FI942728L FI942728L (fi) 1994-06-10
FI942728A0 true FI942728A0 (fi) 1994-06-10

Family

ID=10706001

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942728A FI942728A0 (fi) 1991-12-10 1992-12-10 Lääkeainekoostuksia parenteraaliseen käyttöön

Country Status (12)

Country Link
US (1) US5571534A (cs)
EP (1) EP0616529B1 (cs)
JP (1) JP3558344B2 (cs)
AT (1) ATE149828T1 (cs)
AU (1) AU667861B2 (cs)
CA (1) CA2125408C (cs)
DE (1) DE69218241T2 (cs)
FI (1) FI942728A0 (cs)
GB (1) GB9126209D0 (cs)
NO (1) NO308578B1 (cs)
WO (1) WO1993011757A1 (cs)
ZA (1) ZA929592B (cs)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
ATE227979T1 (de) * 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
GB9411115D0 (en) * 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
GB9609171D0 (en) 1996-05-02 1996-07-03 Orion Yhtymae Oy Antioxidant compounds
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
DK0893121T3 (da) * 1997-06-27 2002-06-17 Akzo Nobel Nv Flydende oral medicinopløsning
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
NZ527522A (en) * 1998-05-07 2005-04-29 Univ Tennessee Res Corp Use of a chemopreventative agent in a method for chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413535B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
DK1135193T3 (da) * 1998-12-04 2002-12-02 Max Delbrueck Centrum Middel til tumorterapi, som er baseret på liposomer, og som indeholder tamoxifen
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US20040029831A1 (en) * 2000-05-31 2004-02-12 Kava Pharmaceuticals, Inc. Extracts of kava-kava
US6303157B1 (en) 2000-05-31 2001-10-16 Kava Pharmaceuticals, Inc. Extracts of kava-kava
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
PT1666033E (pt) 2001-11-29 2009-02-09 Gtx Inc Prevenção e tratamento de osteoporose induzida pela falta de androgénio
US20050239747A1 (en) * 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
WO2006001035A2 (en) * 2004-06-28 2006-01-05 Lifecare Innovations Pvt. Ltd. Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof.
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
ES2369554T3 (es) * 2004-09-24 2011-12-01 Rfe Pharma Llc Carboxi-amido-triazoles para el tratamiento local de enfermedades oculares.
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
ES2401285T3 (es) * 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
WO2007078060A1 (en) * 2005-12-30 2007-07-12 Amorepacific Corporation Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same
DK2076268T3 (da) 2006-10-19 2013-04-22 Genzyme Corp Roscovitin til behandling af visse cystiske sygdomme
RS55148B1 (sr) 2009-03-30 2016-12-30 Eisai R&D Man Co Ltd Smeša lipozoma
JP5622719B2 (ja) * 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
WO2013008083A1 (en) 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen
SMT201800233T1 (it) 2011-09-18 2018-07-17 Euro Celtique Sa Composizione farmaceutica comprendente un inibitore di hdac e un ciclopolisaccaride
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
CN105246902B (zh) 2013-03-15 2018-05-04 加利福尼亚大学董事会 无环核苷膦酸二酯
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9493493B2 (en) 2014-09-15 2016-11-15 The Regents Of The University Of California Nucleotide analogs
CN105748442B (zh) * 2016-04-07 2019-04-12 天津中医药大学 一种红景天苷及他莫昔芬的双载药抗乳腺癌纳米制剂的制备方法
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
EP3471722B1 (en) 2016-06-17 2023-10-25 The Trustees of the University of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
RS64029B1 (sr) * 2017-06-30 2023-03-31 Celgene Corp Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer
CN117224487B (zh) * 2023-10-07 2025-08-08 山东新时代药业有限公司 一种枸橼酸托瑞米芬脂质体、制备方法及制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5793909A (en) * 1980-12-03 1982-06-11 Sankyo Co Ltd Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation
FR2502951B1 (fr) * 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
FI67538C (fi) * 1982-05-27 1985-04-10 Farmos Oy Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten
DE3331459A1 (de) * 1982-08-31 1984-03-01 Martin Dr.med. 6900 Heidelberg Berger Zubereitung zur tumorbehandlung mit einem gehalt an diazoxid und dessen verwendung
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
JP2847783B2 (ja) * 1988-08-11 1999-01-20 日清製粉株式会社 抗癌活性増強剤
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
DE3837596A1 (de) * 1988-11-05 1990-05-10 Rosink Gmbh & Co Kg Kannenstock
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
CA2084208A1 (en) * 1990-05-17 1991-11-18 Barry Markaverich Growth inhibitors and methods of treating cancer and cell proliferative diseases

Also Published As

Publication number Publication date
ATE149828T1 (de) 1997-03-15
NO308578B1 (no) 2000-10-02
NO942155D0 (no) 1994-06-09
AU3159993A (en) 1993-07-19
EP0616529B1 (en) 1997-03-12
FI942728A7 (fi) 1994-06-10
JPH07501813A (ja) 1995-02-23
EP0616529A1 (en) 1994-09-28
CA2125408C (en) 2004-04-20
GB9126209D0 (en) 1992-02-12
FI942728L (fi) 1994-06-10
DE69218241D1 (de) 1997-04-17
CA2125408A1 (en) 1993-06-23
AU667861B2 (en) 1996-04-18
ZA929592B (en) 1993-08-06
US5571534A (en) 1996-11-05
JP3558344B2 (ja) 2004-08-25
DE69218241T2 (de) 1997-06-19
WO1993011757A1 (en) 1993-06-24
NO942155L (cs) 1994-06-10

Similar Documents

Publication Publication Date Title
FI942728A0 (fi) Lääkeainekoostuksia parenteraaliseen käyttöön
EE03108B1 (et) Farmatseutiline kompositsioon
FI981777A0 (fi) Farmaseuttinen ainekoostumus
FI922316L (fi) Farmaceutisk sammansaettning
NO920067D0 (no) Foradditiv for droevtyggere
DK0585252T3 (da) Farmaceutiske formuleringer
DE4291156T1 (de) Verbesserte pharmazeutische Zusammensetzungen
NO923127L (no) Farmasoeytisk kombinasjonsformulering
FI930737A7 (fi) Asialoglykoproteiiniin sidottu lääkeaine
NO923859D0 (no) Medikament
MX9200622A (es) Composicion farmaceutica
MX9200146A (es) Composiciones farmaceuticas deglutibles
IT1290797B1 (it) Composizioni farmaceutiche stabilizzate
DE69217020D1 (de) Arzneimittel mit gesteuerter Wirkstoffabgabe
NO306381B1 (no) Farmasöytisk ampulle
FI921785A7 (fi) Farmaceutisk foerening
FI921786A7 (fi) Farmaceutisk foerening
FI920845A7 (fi) Interleukiini-2:ta sisältäviä farmaseuttisia koostumuksia
BR9206845A (pt) Composto famacêutico
IL98791A0 (en) Anti-cancer pharmaceutical compositions
FI941696A0 (fi) Systeemi lääkkeen oraaliseen antoon
SE9103213D0 (sv) Farmaceutisk komposition
SE9101348D0 (sv) Pharmaceutical composition
IL95508A0 (en) Pharmaceutical compositions for transdermal administration
NO942076D0 (no) Farmasöytisk blanding

Legal Events

Date Code Title Description
MA Patent expired